1,721,669 research outputs found
Nutraceuticals - shedding light on the grey area between pharmaceuticals and food
No full textThe term ‘nutraceutical’, originally coined in 1989 by Stephen
DeFelice, founder and chairman of the Foundation for
Innovation in Medicine (DeFelice, 1989), is a portmanteau of
the words ‘nutrition’ (indicating a nourishing food or food
component) and ‘pharmaceutical’ (with reference to a drug),
the concept of nutraceutical and potential has been described
and widely assessed in the following years since 1995
Use of comparative molecular field analysis and cluster analysis in series design.
No full textAn approach to series design in the framework of the comparative molecular field analysis three-dimensional quantitative structure-activity relationship (CoMFA 3D-QSAR) method is proposed. This procedure is based on performing cluster analysis on principal components generated from CoMFA energy descriptors. The results of our case study suggest that a CoMFA model derived from a relatively small series of properly selected structures can provide nearly the same amount of information which could be obtained from a much larger data set of analogue
GOMEZ-MONTERREY I. M., CAMPIGLIA P., MAZZONI O., NOVELLINO E., DIURNO M. V. (2001). Cycloaddition reactions of thiazolidine derivatives. An approach to the synthesis of new functionalized heterocyclic systems. TETRAHEDRON LETTERS. vol. 42, pp. 5755-5757 ISSN: 0040-4039.
No full textFrom pharmaceuticals to nutraceuticals: bridging disease prevention and management
No full textNutraceuticals, up today, do not have a specific definition distinct from those of other food-derived categories, e.g. food supplements, herbal products, pre and probiotics, functional foods, etc. They have, however, a pharmacological beneficial effect on health. Many studies have been recently addressed to assess their safety, efficacy, and regulation since they are getting growing attention by market and research, with the aim to clear the difference between them and other market available food-derived products that claim beneficial effect on health. Areas covered: The understanding of the potential mechanisms of action of pharmaceutically active substances contained in nutraceuticals that may improve health and reduce the risk of pathological conditions while enhancing overall well-being is the challenge for nutraceuticals to be considered as a preventive and therapeutic efficient tool in facing some diseases. Expert commentary: It is of utmost importance to have a proper and unequivocal definition of nutraceuticals and a shared regulation. Nevertheless, there is a lack of clear information and, often, the claimed health benefits may not be properly substantiated by safety and by efficacy in vivo data, which can induce false expectations and miss the target for a product to be effective, as claimed
GOMEZ-MONTERREY I. M., CAMPIGLIA P., MAZZONI O., NOVELLINO E., DIURNO M. V. (2001). Cycloaddition reactions of thiazolidine derivatives. An approach to the synthesis of new functionalized heterocyclic systems. TETRAHEDRON LETTERS. vol. 42, pp. 5755-5757 ISSN: 0040-4039.
No full text
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
Full text link“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Cdc25B phosphatase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective.
No full textThe Cdc25 phosphatases (Cdc25A, Cdc25B, and Cdc25C in humans), which are responsible for dephosphorylating specific tyrosine/ threonine residues on cyclin dependent kinases (CDKs), function as essential regulators of cell cycle control during normal eukaryotic cell division and as mediators of the checkpoint response in cells with DNA damage. Because overexpression of Cdc25A and Cdc25B has been linked to numerous cancers and often correlates with a poor clinical outcome, both academia and industry have devoted substantial research effort in establishing the basic underlying molecular mechanisms and in identifying novel, specific and potentially useful inhibitors of Cdc25 as potential anticancer drugs. Over the past year, dozens of research papers and patent applications describing new Cdc25 inhibitors belonging to different structural classes have been disclosed. In this review, we give an overview on the current status in the field of medicinal chemistry of Cdc25B inhibitors. In addition, molecular modeling studies aimed to clarify the molecular mechanism of inhibition as well as the pharmacophoric features critical for design of new and selective Cdc25B inhibitors are also discussed
- …
